RESOURCES

Home

Case Study: TraceLink | FDA Pilot - Product Traceability Under 2023 DSCSA Regulations - A Business Process-Led Design for a Blockchain Network



TraceLink's breakthrough blockchain solution, Trace Histories, can help pharma clients comply with US Drug Supply Chain Security Act regulations which go into effect in 2023. With Trace Histories, customers can respond to product trade requests while simultaneously safeguarding confidential commercial information. Read our new poster, which was featured at FutureLink Nashville, for additional details.

FDA Pilot: Product Traceability under 2023 DSCSA Regulations – A Business Process-Led Design for a Blockchain Network

Amanda Bettman, Product Manager, Blockchain and Trace Histories; Brian Daleiden, VP, Industry Marketing and Community, TraceLink

Summary: In addition to serialization and verification, DSCSA 2023 regulations contain requirements concerning the ability of supply chain participants to conduct a Product Trace. TraceLink, in partnership with industry leaders, is conducting an FDA pilot using our Trace Histories solution as a tool to examine a solution that would enable the development and deployment of a standardized, interoperable network.



VIEW POSTER SESSION GALLERY

Case Study

DSCSA for Manufacturers

Regulatory/Compliance

United States

Subscribe to Agile Supply Chain Insights

Subscribe to stay informed with the latest patient-centric agile supply chain thought leadership content.